Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT03226249
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 500
- Registration Number
- NCT03159897
- Locations
- 🇮🇹
Ospedale Madonna delle Grazie - Ematologia, Matera, Italy
🇮🇹Presidio ospedaliero "A. TORTORA", Pagani, Italy
🇮🇹Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 378
- Registration Number
- NCT03070392
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT03033914
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 23
- Registration Number
- NCT03023124
- Locations
- 🇮🇹
Nuovo Ospedale di Prato, Prato, Firenze, Italy
🇮🇹Policlinico Universitario Campus Biomedico, Roma, RM, Italy
🇮🇹IRCCS Istituto ortopedico Rizzoli, Bologna, Italy
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 325
- Registration Number
- NCT03016819
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 110
- Registration Number
- NCT03004833
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT02979522
- Locations
- 🇧🇷
ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil
🇮🇹Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy
🇧🇷Hospital Santa Marcelina, Sao Paulo, Brazil
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- GALIA AVRAHAMI
- Target Recruit Count
- 2200
- Registration Number
- NCT02797717
- Locations
- 🇮🇱
Schneider children's medical center, Petach-Tikva, Israel
HD21 for Advanced Stages
- Conditions
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1500
- Registration Number
- NCT02661503
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.